Sabin Dang, MD
Retina Specialist · Brentwood, MONPI 1740579531
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $105,205 of the $174,282 with a category attached, or 60.4%. 21 manufacturers reported payments, led by Genentech USA, Inc. at 45.7% of the total. Reporting peaked in 2024 at $57,123 and has fallen 80.2% since, to $11,288 in 2025. Among retina specialist clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $767.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$80K
- Regeneron Healthcare Solutions, Inc.$62K
- Regeneron$11K
- Harrow Eye, LLC$9K
- Bausch & Lomb Americas Inc.$6K
- Apellis Pharmaceuticals, Inc.$3K
- plus $4K from 15 others
Across 43 payments — averaging $7368.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$254K
- Bausch Health US, LLC$29K
- Bausch & Lomb Americas Inc.$20K
- Regeneron$10K
- F. Hoffmann-la Roche AG$5K
What the payments were for
- Consulting fees$45,87726%
- Speaking & faculty fees$105,20560%
- Travel & lodging$15,1959%
- Food & beverage$7,9695%
- Gifts$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 71 | $79,724 |
| Regeneron Healthcare Solutions, Inc. | 72 | $62,411 |
| Regeneron | 14 | $10,605 |
| Harrow Eye, LLC | 6 | $8,627 |
| Bausch & Lomb Americas Inc. | 16 | $6,010 |
| Apellis Pharmaceuticals, Inc. | 1 | $3,024 |
| Eyepoint US, Inc. | 2 | $2,018 |
| Carl Zeiss Meditec, Inc. | 5 | $242 |
| Amgen | 2 | $239 |
| Astellas Pharma US Inc | 8 | $223 |
| Alimera Sciences, Inc. | 3 | $175 |
| Biogen | 5 | $173 |
| Genentech, Inc. | 2 | $161 |
| AbbVie(2 entities) | 8 | $148 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $143 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $122 |
| Alcon | 2 | $110 |
| Novartis | 4 | $73 |
| Stryker | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$76,346
- EYLEA$48,758
- EYLEA HD$22,630
- IHEEZO$8,549
- TRIESENCE$8,549
- SUSVIMO$2,520
- EYP-1901$2,018
- XIPERE$1,554
- VISUDYNE$1,497
- STELLARIS ELITE$1,000
- Tecnis IOL$243
- enVista MX60 IOL$243
- Iluvien$125
- STELLARIS$124
- CATALYS SYSTEM$122
- PAVBLU$104
How this compares
$174,282 in reported general payments places this provider in the 95th percentile of 45 retina specialist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 34 | $11,960 |
| Prednisolone Acetate | 179 | $6,742 |
| Bromfenac Sodium | 46 | $6,537 |
| Lotemax SmLoteprednol Etabonate | 17 | $4,230 |
| Ofloxacin | 120 | $1,171 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 88 | $775 |
| Latanoprost | 48 | $541 |
| Dorzolamide Hcl | 22 | $501 |
| Ketorolac Tromethamine | 30 | $446 |
| Brimonidine Tartrate | 51 | $314 |
| Timolol Maleate | 36 | $231 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 11 | $110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $143 | $16,19151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 45 retina specialist providers in Missouri.
Other retina specialist in Brentwood
- Kevin BlinderBrentwood$333K
- Athanasios PapakostasBrentwood$85K
- Alia DurraniBrentwood$53K
- Barton BlackorbyBrentwood$31K
- Ollya FromalBrentwood$14K
- Nicholas IafeBrentwood$9K
- Dillan PatelBrentwood$5K
- Bradley SmithBrentwood$5K
- William AndersonBrentwood$4K
- Prithvi BomdicaBrentwood$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.